Focus Fund
  • Home
  • About
    • Mission & Values
    • Investment Strategy
  • Team
  • Portfolio
  • News
  • Investor Portal
  • Contact
Select Page

News

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy

PR Newswire | 03/07/22

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

PR Newswire | 02/17/2022

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers

PR Newswire | 05/26/2021

Mereo and Focus Fund Announce Etigilimab partnership with MD Anderson

Mereo BioPharma | 04/30/21

MD Anderson Brings Underdogs into the Fight Against Cancer with Focus Fund

BioSpace | 10/21/20

Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials

PR Newswire | 10/20/20

At The Focus Fund, we invest in promising technologies that are close to being tested in humans. Our objective is to leverage MD Anderson resources to provide investors with superior risk-adjusted returns.

Find out how you can partner with us

Contact

At the Cancer Focus Fund, we invest in promising therapies in late preclinical development through Phase I and Phase Ib/II clinical trials. Our objective is to provide support to accelerate the development of these therapeutics together with the clinical trials expertise and infrastructure of MD Anderson.

Texas Medical Center

2450 Holcombe Boulevard
Houston, TX 77021

Shreveport

2031 Kings Highway
Shreveport, LA 71103

Pages

  • Home
  • About
  • News
  • Portfolio
  • Contact
  • Team

Copyright © 2022 Focus Fund|Developed by RP Agency